What the FDA labels say about taking them together
Nateglinide and octreotide
Nateglinide's FDA label of February 24, 2025 names octreotide in its drug interactions section; the octreotide labels PlainMeds reads (4) do not name nateglinide. The nateglinide label: “Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin …”
Check it at the source: the nateglinide FDA label on DailyMed (effective February 24, 2025, Strides Pharma Science Limited); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the nateglinide label say about octreotide?
Nateglinide label, drug interactionsDrugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). Intervention: Dose increases and increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs.
Source: FDA drug label (Nateglinide), Strides Pharma Science Limited, effective February 24, 2025 (SPL set 0ccf9b07-3c21-482d-abeb-a06ceb482c7b), via openFDA; the full label on DailyMed
What does the octreotide label say about nateglinide?
Octreotide's label (effective July 22, 2026) and its 3 other brand-application labels do not name nateglinide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nateglinide | Octreotide | |
|---|---|---|
| Labeled for | Type 2 diabetes | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.179 per tablet 60 mg tablet | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once